Abstract: Rosacea is a chronic inflammatory skin disease characterized by facial erythema, telangiectasia, papules, and pustules. Some patients respond poorly to traditional treatments or experience adverse reactions. In recent years, Janus kinase (JAK) inhibitors, as a new targeted drugs, have attracted considerable attention due to their significant efficacy in various inflammatory and autoimmune diseases, and their potential in the treatment of rosacea has also been gradually revealed. We review the mechanisms, efficacy, and safety of JAK inhibitors, including tofacitinib, abrocitinib, upadacitinib, and ruxolitinib, in the treatment of rosacea.

Key words: rosacea, JAK kinase inhibitor, tofacitinib, abrocitinib, upadacitinib, ruxolitinib